CDH1 and cancer: Western blot assays showed that the decreased CDH1 expression and enhanced mesenchymal (CDH2 and vimentin) and cancer stemness (CD44, ABCG2, OCT4 and MYC) marker expression were abolished after treating MCF-7OE-UBE2O cells with rapamycin (Fig. 7a).